Contents

Issue 148 • November 2024

In association with

Cover Story

Cell and gene therapy approvals drive paradigm change in manufacturing

Feature

How the Covid-19 pandemic will help researchers with the mpox emergency

Analyst Comment

Keytruda and Opdivo: a decade review

In Depth

Cell and gene therapy approvals drive paradigm change in manufacturing

After the Lykos debacle, what’s next for psychedelic therapies?

Compounding pharmacies caught in counterfeit controversy

How the Covid-19 pandemic will help researchers with the mpox emergency

Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts

Clinical research in the UK must build on industry collaboration, says NIHR director

Keytruda and Opdivo: a decade review

Briefing

News in Numbers

Latest News

Latest Deals

Project Updates

In Data

M&A activity in the mining industry

Hiring activity in the mining industry decreased

Patent activity in the mining industry decreased

Sentiment in the mining industry increased

Thematic Take

AI in the healthcare sector

Powered by

11/18/2024 10:28:14
  • Home | Cell and gene therapy approvals drive paradigm change in manufacturing
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Syngene Company Insight
  • Syngene
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • PCI Pharma Services
  • AlfatestLAB - CPHI
  • RHEACELL Company Insight
  • In Depth
  • Cell and gene therapy approvals drive paradigm change in manufacturing
  • After the Lykos debacle, what’s next for psychedelic therapies?
  • Compounding pharmacies caught in counterfeit controversy
  • How the Covid-19 pandemic will help researchers with the mpox emergency
  • Iterum’s oral sulopenem acceptance hinges on antibiotic stewardship efforts
  • Clinical research in the UK must build on industry collaboration, says NIHR director
  • Keytruda and Opdivo: a decade review
  • Alphial - CPHI
  • Rephine
  • Rephine - CPHI
  • Thematic Take: AI
  • Thematic Take: contents
  • Foreword: Generative AI as a force of creative destruction
  • The road to advanced AI capabilities
  • AI technology: Market size and growth forecasts
  • Timeline: a history of AI
  • The impact of AI on the pharma sector
  • Case studies: AI in pharma
  • Latest news: AI in pharma
  • AI boom set to revolutionise healthcare in Europe
  • How NVIDIA grew with the healthcare market instead of pushing into it
  • Capturing the genAI boom for drug development
  • New AI model boosts early osteoporosis diagnosis for ageing populations
  • Impact of AI on metabolic disorder clinical trials
  • Resist temptation to rapidly roll out AI – executives must focus on talent and training
  • Is AI really helping employees?
  • Is your business ready for the rise of AI agents?
  • Deal activity related to AI in the pharma industry since 2021
  • Sponsored Supplements
  • BEA Technologies
  • Techniconsult Firenze - CPHI
  • Science4Tech
  • Listings
  • Events
  • Excellence Awards
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
10/07/2024 00:00:00